Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.

With the number of deals being inked in biopharma continuing apace, the UK firm spoke to Scrip about how to negotiate the line between what big pharma wants and what a biotech is likely to get.